[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"deep-vein-thrombosis-dvt\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:deep-vein-thrombosis-dvt":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,40,79,103,133,163,185,207],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100650594","clinical-trial-of-thrombectomy-systems-100650594",false,"NCT07749820","Clinical Trial of Thrombectomy Systems","A Prospective, Multicenter, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Thrombectomy Systems for the Treatment of Lower Extremity Deep Vein Thrombosis","Inclusion Criteria:\n\n* Age ≥18 years；\n* Confirmed lower extremity deep vein thrombosis (DVT) by imaging, meeting at least one of the following: (1) acute iliofemoral or femoropopliteal DVT; or (2) subacute iliofemoral DVT;\n* Investigator-assessed life expectancy ≥1 year;\n* Willing to participate in this study and provide written informed consent.\n\nExclusion Criteria:\n\n* Infection at the puncture site or severe systemic infection;\n* Inability to establish vascular access or difficulty in advancing the guidewire through the lesion;\n* Hemodynamically unstable pulmonary embolism;\n* The target lesion thrombosis is recurrent after prior interventional therapy;\n* A venous stent has been implanted in the target lesion, or the presence of an inferior vena cava filter that interferes with device deployment;\n* Bilateral lower extremity deep vein thrombosis requiring thrombectomy in the same procedure;\n* Active bleeding within the past 30 days, including severe intracranial, gastrointestinal, or urinary tract bleeding;\n* History of hemorrhagic or ischemic stroke within the past 30 days;\n* Known severe coagulation disorder or bleeding tendency;\n* Severe hepatic or renal impairment;\n* Known allergy or significant hypersensitivity to iodine-based contrast media, thrombolytic agents, anticoagulants, or antiplatelet drugs;\n* Known conditions such as severe hyperthyroidism, multiple myeloma, or severe heart failure that preclude tolerance to percutaneous transluminal angioplasty;\n* Pregnant or lactating women, or women planning to become pregnant during the study period;\n* Currently participating in any other clinical trial of a drug or medical device;\n* Any other condition that, in the investigator's judgment, makes the subject ineligible for participation in this trial.","ALL","18 Years",{"count":19,"type":20},167,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study plans to enroll 167 subjects. Subject enrollment and treatment details will be documented, and follow-up assessments will be conducted at screening, on the procedure day, before discharge, and at 1, 3, and 6 months after the procedure, to assess the safety and efficacy of the peripheral thrombectomy system for the treatment of lower extremity deep vein thrombosis.",[26],"Deep Vein Thrombosis (DVT)","RECRUITING","2026-08-05",{"date":30,"type":31},"2026-08-07","ACTUAL",{"date":33,"type":20},"2026-08-30",{"date":35,"type":20},"2027-12-30",{"name":37,"class":38},"BrosMed Medical Co., Ltd","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":50,"conditions":51,"keywords":55,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100647880","phase-4-extended-prophylactic-anticoagulation-following-spinal-surgery-for-metastatic-disease-100647880","NCT07713875","Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease","Inclusion Criteria:\n\n* Age 18 years or older\n* Undergone spinal surgery (any approach) for treatment of vertebral metastatic disease at UPMC Presbyterian, Shadyside, or Mercy Hospital\n* Planned for discharge to home or acute rehabilitation facility (not hospice)\n* Willing and able to provide written informed consent\n* Able to take oral medications\n* Access to a telephone for follow-up calls\n\nExclusion Criteria:\n\n* Already receiving therapeutic anticoagulation for another indication (e.g., atrial fibrillation, prior VTE, mechanical heart valve)\n* Planned initiation of therapeutic anticoagulation within the next 30 days for another indication\n* Known allergy or hypersensitivity to apixaban\n* History of pathological bleeding (e.g., intracranial hemorrhage, gastrointestinal bleeding requiring transfusion or endoscopic intervention within the past 6 months)\n* Active bleeding at time of planned enrollment\n* Platelet count less than 50,000\u002Fmm³ at time of enrollment\n* Hemoglobin less than 8 g\u002FdL at time of enrollment\n* Serum creatinine greater than 2.5 mg\u002FdL\n* ALT or AST greater than 3 times the upper limit of normal\n* Total bilirubin greater than 2 times the upper limit of normal\n* Known severe hepatic impairment (Child-Pugh Class C)\n* Pregnancy or breastfeeding\n* Women of childbearing potential unwilling to use adequate contraception during study participation\n* History of proximal gastrointestinal resection (i.e., gastrectomy and\u002For proximal small bowel resection) that might alter oral drug absorption\n* Concurrent use of strong dual inhibitors of CYP3A4 and P-gp or moderate CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, diltiazem)\n* Concurrent use of strong dual inducers of CYP3A4 and P-gp (rifampin, carbamazepine, phenytoin, St. John's Wort)\n* Inability to safely discontinue all antiplatelet medications for the 30-day study drug period, as determined by the treating cardiologist or prescribing physician (aspirin, clopidogrel, ticagrelor)\n* Inability or unwillingness to discontinue chronic NSAID use during the 30-day study drug period (as-needed use less than 3 days per week is acceptable)\n* Planned surgery or invasive procedure within the next 30 days\n* Hospital length of stay 30 days or greater\n* Prisoner or incarcerated individual\n* Any other condition that, in the investigator's opinion, would make the subject unsuitable for study participation or unable to comply with study procedures",{"count":47,"type":20},50,[49],"PHASE4","People who have surgery on their spine to treat cancer that has spread (metastatic disease) have a high chance of developing dangerous blood clots in the legs or lungs. These blood clots are called deep vein thrombosis (DVT) or pulmonary embolism (PE). In a review of patients at UPMC who had this type of surgery, about 15 out of 100 developed a blood clot within 90 days of leaving the hospital.\n\nRight now, patients receive blood-thinning medicine only while they are in the hospital after surgery. Once they go home, the medicine is stopped. There are no guidelines telling doctors whether blood-thinning medicine should continue after patients go home from spine surgery for cancer. However, for other types of major cancer surgery, studies have shown that continuing blood-thinning medicine for about 4 weeks after surgery can help prevent blood clots.\n\nThis study will test whether taking a blood-thinning medicine called apixaban (brand name Eliquis) by mouth for 30 days after leaving the hospital can help prevent blood clots in patients who have had spine surgery for cancer that has spread. The dose used in this study (2.5 mg twice a day) is the same dose approved by the U.S. Food and Drug Administration (FDA) for preventing blood clots after hip and knee replacement surgery.\n\nAbout 50 adults at UPMC will take part. Participants will take apixaban for 30 days starting the day after hospital discharge. The study team will call participants by phone three times - about 2 days, 31 days, and 91 days after discharge - to check on their health, ask about any bleeding or blood clot symptoms, and assess medication use. No extra clinic visits are required. Results will be compared to a group of 68 patients who had the same type of surgery in the past but did not take apixaban after leaving the hospital.\n\nThe main goal is to find out if apixaban reduces the rate of blood clots within 90 days of hospital discharge. The study will also track bleeding events and other side effects to determine if this approach is safe. The study hypothesis is that extended blood-thinning medicine after surgery will reduce blood clots compared to the current approach of stopping this medicine at hospital discharge.",[52,26,53,54],"Venous Thromboembolism (VTE)","Pulmonary Embolism (PE)","Spine Metastasis",[56,57,58,59,60,61,62,63,64,65,66],"Apixaban","Eliquis","Extended thromboprophylaxis","Postoperative anticoagulation","Spine surgery","Cancer surgery","VTE prophylaxis","Direct oral anticoagulant","DOAC","Factor Xa inhibitor","Metastatic bone disease","NOT_YET_RECRUITING","2026-07-14",{"date":70,"type":31},"2026-07-20",{"date":72,"type":20},"2026-08",{"date":74,"type":20},"2027-12",{"name":76,"class":77},"James Bayley","OTHER",3,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":100,"locationsCount":102},"100644117","impedance-plethysmography-based-deep-vein-thrombosis-monitoring-during-catheter-directed-thrombolysis-100644117","NCT07665320","Impedance Plethysmography Based Deep Vein Thrombosis Monitoring During Catheter-directed Thrombolysis","Inclusion Criteria for Patients group:\n\n* Age: 18 or older;\n* DVT detected on other lower limb;\n* Suitable for CDT treatment;\n* Ability to give informed consent;\n* Volunteering for the study.\n\nExclusion Criteria for Patients group:\n\n* Age under 18 years;\n* Inability to give informed consent;\n* Denial;\n* Too injured skin in the measurement area\n\nInclusion Criteria for Healthy volunteers group:\n\n* Age: 18 or older;\n* Ability to give informed consent;\n* Volunteering for the study\n\nExclusion Criteria for Healthy volunteers group:\n\n* Diagnosed DVT in lower limbs;\n* Age under 18 years;\n* Inability to give informed consent;\n* Denial;\n* Too injured skin in the measurement area.",true,{"count":87,"type":20},40,"OBSERVATIONAL","The purpose of this study is to collect data on blood circulation using a multi-frequency impedance plethysmography device developed in the ThrombUS+ project. Impedance plethysmography (IPG) is a non-invasive method that measures changes in blood volume using electrodes placed on the skin. The collected data will be used for device development, the improvement of diagnostic data analysis methods, and AI training.\n\nA total of 40 participants will be recruited for this study, with 20 healthy volunteers in Tampere University and 20 patients undergoing thrombolytic therapy for DVT at Tampere University Hospital.",[26],[92,93],"deep vein thrombosis","DVT","2026-06-24",{"date":96,"type":31},"2026-06-29",{"date":98,"type":31},"2025-07-17",{"date":74,"type":20},{"name":101,"class":77},"Tampere University",2,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100642274","decision-aid-for-anticoagulation-duration-after-unprovoked-venous-thromboembolism-100642274","NCT07659106","Decision Aid for Anticoagulation Duration After Unprovoked Venous Thromboembolism","Enabling and Engaging Patients to Decide Indefinite Versus Short-Term Anticoagulation for Venous Thromboembolism (DECIDE-VTE)","DECIDE-VTE","Inclusion Criteria:\n\n* Age 18 years or older\n* First episode of objectively confirmed unprovoked or weakly provoked venous thromboembolism (VTE)\n* Objectively confirmed proximal deep vein thrombosis and\u002For segmental or greater pulmonary embolism\n* Completed at least 3 months of therapeutic anticoagulation and currently receiving anticoagulation\n* Enrollment within 12 months of diagnosis of the index\u002Fqualifying VTE event\n* Able to provide written informed consent\n* Able to participate in shared decision-making in English or French\n\nExclusion Criteria:\n\n* Recurrent unprovoked or weakly provoked VTE I(i.e. multiple unprovoked\u002Fweakly provoked VTE)\n* Index\u002Fqualifying VTE is a strongly provoked VTE (e.g., associated with major surgery, major trauma, plaster cast immobilization, or prolonged bed rest)\n* Index\u002Fqualifying VTE associated with a persistent strong provoking risk factor (e.g., active cancer or ongoing immobility)\n* Women at very low recurrence risk (HERDOO2 score 0-1)\n* High bleeding risk such that anticoagulation should be discontinued\n* Requirement for long-term anticoagulation for another indication (e.g., atrial fibrillation)\n* Prior dedicated long-term anticoagulation Decision Visit regarding anticoagulation duration",{"count":112,"type":20},850,[23],"Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is a common condition that is typically treated with blood thinners (anticoagulants). After completing at least 3 months of treatment for a first unprovoked or weakly provoked VTE, patients and clinicians must decide whether to stop anticoagulation or continue treatment for a longer period. Continuing anticoagulation reduces the risk of another blood clot but increases the risk of bleeding. Because both options involve important benefits and risks, this decision should reflect the patient's values and preferences.\n\nThe DECIDE-VTE study will evaluate whether a patient decision aid can improve decision-making for patients facing this choice. The decision aid provides evidence-based information about the risks and benefits of continuing versus stopping anticoagulation and includes a values clarification exercise to help patients identify what matters most to them.\n\nThis multicentre batched stepped-wedge cluster randomized trial will be conducted in 12 thrombosis clinics across Canada. Clinics will transition from usual care to implementation of the patient decision aid according to a randomized schedule. The primary outcome is decisional conflict immediately following the anticoagulation decision visit, measured using the Decisional Conflict Scale. Secondary outcomes include patient knowledge, treatment decisions, decisional regret, concordance with the chosen treatment strategy, recurrent venous thromboembolism, major bleeding, all-cause mortality, and implementation outcomes.",[52,26,116],"Pulmonary Embolism",[118,119,120,121,122,123],"Anticoagulation","Patient Decision Aid","Shared Decision Making","Extended Anticoagulation","Decisional Conflict","Stepped-Wedge Cluster Randomized Trial","2026-06-19",{"date":94,"type":31},{"date":127,"type":20},"2026-09",{"date":129,"type":20},"2029-03",{"name":131,"class":77},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",5,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":143,"conditions":144,"keywords":148,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":162},"100600797","cleaner-long-term-assessment-registry---venous-insights-and-efficacy-with-extended-tracking-100600797","NCT07102160","Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking","A Prospective, Multi-Center, Open-Label Clinical Investigation of the Cleaner Vac® Thrombectomy System for Treatment of Lower Extremity Proximal Deep Vein Thrombosis (DVT)","CLEAR-VIEW XT","Inclusion Criteria:\n\nParticipants must meet all the following criteria to be eligible for the study:\n\n1. At least 18 years of age at the time of consent.\n2. Undergo frontline (primary) treatment with Cleaner Vac® Thrombectomy System in the peripheral venous vasculature and have at least one component introduced into the body.\n3. Written informed consent obtained through the IRB-approved ICF.\n\n   For the DVT cohort, participants must meet all criteria above and below to be eligible for the study:\n4. Present with unilateral or bilateral lower extremity DVT involving at least one of the following veins:\n\n   1. Femoral-popliteal vein\n   2. Common femoral vein\n   3. Iliac vein\n   4. Inferior Vena Cava (IVC)\n5. DVT diagnosis confirmed by imaging within 14 days of the index procedure.\n6. Symptomatic DVT with onset within 6 weeks of enrollment.\n\nExclusion Criteria:\n\nSubjects will be excluded from the study if any of the following criteria are met:\n\n1. Contraindication to systemic or therapeutic doses of anticoagulants.\n2. Contraindication to iodinated contrast that cannot be adequately premedicated.\n3. Life expectancy less than 1 year due to advanced malignancy, as determined by the investigator at the time of enrollment\n4. Patients that are pregnant.\n5. Known coagulation disorders both acquired (Heparin Induced Thrombocytopenia, etc.) or genetic (e.g., Factor V Leiden, etc.), thrombophilia, or hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period.\n6. Treatment of target venous segment with thrombolytics within previous 14 days of the index procedure.\n7. Known congenital anatomic anomalies of the inferior vena cava (IVC) or iliac veins.\n8. Known history of a Patent Foramen Ovale (PFO).\n9. Hemoglobin \\\u003C 8.0 g\u002FdL, INR \\> 2.0 before warfarin was started, or platelets \\\u003C 50,000\u002Fµl which cannot be corrected prior to enrollment.\n10. Severe renal impairment (estimated GFR \\\u003C 30 ml\u002Fmin) in patients who are not yet on dialysis. Patients with GFR \\\u003C30 ml\u002Fmin who are already on dialysis can be enrolled.\n11. Patients with intermediate-high risk or high-risk pulmonary embolism (PE) defined as follows:\n\n    1. High-risk PE: Presence of hemodynamic instability, including cardiac arrest, obstructive shock (systolic blood pressure \\\u003C90 mmHg or need for vasopressors with signs of end-organ hypoperfusion), or persistent hypotension (systolic BP \\\u003C90 mmHg or a drop ≥40 mmHg for \\>15 minutes not due to other causes)\n    2. Intermediate-high-risk PE: Hemodynamically stable patients with both right ventricular (RV) dysfunction (on echocardiography or CT) and elevated cardiac biomarkers (e.g., troponin).\n12. Complete infrarenal IVC occlusion.\n13. Chronic non-ambulatory status.\n14. Current enrollment in another investigational device or drug study that may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational studies.",{"count":142,"type":20},185,"The primary objective of this clinical investigation is to evaluate the safety and effectiveness of the Cleaner Vac® Thrombectomy System for the treatment of thrombus in patients with lower extremity proximal deep vein thrombosis (DVT). This prospective, multi-center, open-label study will assess clinical outcomes, device performance, and procedural success in a single DVT study cohort.",[26,145,146,147],"Thrombus in the Peripheral Venous Vasculature","Venous Embolism","Thrombus in the Central and Peripheral Circulatory System, Including Saphenous Vein Grafts",[149,26,150,151,152],"Aspiration Thrombectomy","Peripheral VTE","Venous thromboembolism","Percutaneous mechanical thrombectomy","2026-06-12",{"date":155,"type":31},"2026-06-16",{"date":157,"type":31},"2026-02-04",{"date":159,"type":20},"2029-06",{"name":161,"class":38},"Argon Medical Devices",4,{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":170,"targetDuration":172,"studyType":88,"phases":4,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":39},"100626773","study-of-risk-factors-and-prediction-of-blood-clots-after-lung-cancer-surgery-100626773","NCT07439991","Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery","Prospective Cohort Study on Risk Factors and Machine Learning-Based Prediction of Postoperative Venous Thromboembolism in Patients Undergoing Lung Cancer Surgery","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Patients undergoing surgical resection for lung cancer\n3. Postoperative hospital stay ≥ 48 hours\n4. Availability of perioperative clinical, laboratory, and imaging data\n5. Willingness to provide informed consent and participate in 30-day follow-up\n\nExclusion Criteria:\n\n1. Pre-existing deep vein thrombosis (DVT) or pulmonary embolism (PE) before surgery\n2. Preoperative or ongoing anticoagulation therapy for ≥ 2 weeks\n3. Severe coagulation disorders or bleeding diseases\n4. Severe hepatic, renal, or hematologic dysfunction, or uncontrolled systemic infection\n5. Concurrent major organ surgery (e.g., cardiac, liver surgery)\n6. Pregnancy or lactation\n7. Incomplete postoperative follow-up data",{"count":171,"type":20},900,"30 Days","The goal of this observational study is to learn about the risk factors and prediction of postoperative venous thromboembolism (VTE) in patients undergoing lung cancer surgery. The main question it aims to answer is:\n\nWhich clinical, surgical, and laboratory factors are associated with the development of postoperative deep vein thrombosis (DVT) in lung cancer surgery patients, and can machine learning models accurately predict individual risk?\n\nParticipants undergoing lung cancer surgery will be prospectively followed for 30 days after surgery. Perioperative clinical data, laboratory results, and imaging findings will be collected to identify VTE risk factors and to develop a predictive model.",[175,26,52],"Lung Cancer (Diagnosis)","2026-02-23",{"date":178,"type":31},"2026-02-27",{"date":180,"type":31},"2024-11-01",{"date":182,"type":20},"2029-11-30",{"name":184,"class":77},"The First Hospital of Jilin University",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":21,"phases":193,"briefSummary":194,"conditions":195,"keywords":196,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":39},"100585966","progressive-gait-training-after-first-time-deep-venous-thrombosis-clinical-effectiveness-and-involved-mecanisms-the-dvt-cph-rct-100585966","NCT06909240","Progressive Gait Training After First-time Deep Venous Thrombosis: Clinical Effectiveness and Involved Mecanisms (The DVT-Cph RCT)","Inclusion Criteria:\n\n* 18 years or above\n* First time lower extremity DVT\n* Hospitalized at the Emergency Department\n* Can cooperate cognitively and physically (patient reported)\n\nExclusion Criteria:\n\n* Patients without a Danish social security number\n* Terminal patients\n* Patients who do not understand or speak Danish",{"count":192,"type":20},152,[23],"The DVT-Cph RCT aims to investigate:\n\n1. if progressive gait training in combination with standard care is superior to standard care on quality of life in patients with first time lower extremity deep venous thrombosis (clinical effectiveness part).\n2. the association between progressive gait training and disease progression, late complications such as post throbotic syndrome, and severity of venous thromboembolism conditions in patients with first time lower extremity deep venous thrombosis (mechanistic part).",[26],[197],"Physical activity","2026-01-22",{"date":200,"type":31},"2026-01-23",{"date":202,"type":31},"2025-11-15",{"date":204,"type":20},"2030-02-01",{"name":206,"class":77},"Hvidovre University Hospital",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":217,"conditions":218,"keywords":219,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":39},"100221153","vteval-project---prospective-cohort-studies-to-evaluate-and-improve-diagnostics-management-strategies-and-risk-stratification-in-vte-100221153","NCT02156401","VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE","VTEval Project - Three Observational, Prospective Cohort Studies Including Biobanking to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in Venous Thromboembolism","VTEval","Inclusion Criteria:\n\n* Age ≥18 years and Informed written consent\n* Clinical condition:\n\n  * Cohort 1: Clinical suspicion of acute PE (with or without DVT)\n  * Cohort 2: Clinical suspicion of acute DVT (without symptomatic PE)\n  * Cohort 3: Incidentally diagnosed VTE",{"count":216,"type":20},2000,"Venous thromboembolism (VTE) with its two clinical manifestations deep vein thrombosis (DVT) and pulmonary embolism (PE) is a life-threatening disease that is associated with considerable morbidity and mortality. The incidence of VTE increases with age and it - as the third most common cardiovascular disease after ischemic heart disease and stroke - represents an important public health problem in industrialized countries with several aspects in need to be addressed.\n\nVTEval Project includes three long-term prospective observational studies to evaluate and improve VTE diagnostics and management, treatment and outcome. The aims of the project include a systematic assessment of VTE, i.e. disease status (symptoms, clinical and subclinical aspects) and risk profiles (classic, psychosocial and environmental factors), using a system-oriented approach. VTEval collects three large prospective cohorts of patients with suspected and incident VTE consisting of individuals with a clinical suspicion of acute PE, individuals with a clinical suspicion of acute DVT, and individuals with incidental diagnosis of VTE).\n\nThe standardized and harmonized data acquisition of the study establishes a sustainable resource for comprehensive research on VTE, thus providing the basis for both short- and long-term analysis.",[52,26,53],[151,220,221,222,223,224],"Deep vein thrombosis","Pulmonary embolism","Cohort study\u002Fepidemiology","Outcome","Prognosis","2024-06-14",{"date":227,"type":31},"2024-06-17",{"date":229,"type":31},"2013-04",{"date":231,"type":20},"2030-07",{"name":233,"class":77},"Johannes Gutenberg University Mainz"]